These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 11932875)

  • 21. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?
    van der Veen MJ; Dinant HJ; van Booma-Frankfort C; van Albada-Kuipers GA; Bijlsma JW
    Ann Rheum Dis; 1996 Apr; 55(4):218-23. PubMed ID: 8733437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating interleukin-6 as a biomarker in a randomized controlled trial of modified-release prednisone vs immediate-release prednisolone, in newly diagnosed patients with giant cell arteritis.
    Miler E; Stapleton PP; Mapplebeck S; Mackerness C; Gayford D; Aung T; Wilson L; Schofield P; Dasgupta B
    Int J Rheum Dis; 2019 Oct; 22(10):1900-1904. PubMed ID: 31531960
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and adverse effects of different corticosteroid dose regimens in temporal arteritis: a retrospective study.
    Nesher G; Rubinow A; Sonnenblick M
    Clin Exp Rheumatol; 1997; 15(3):303-6. PubMed ID: 9177927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial.
    Tuckwell K; Collinson N; Dimonaco S; Klearman M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Unizony SH; Stone JH;
    Semin Arthritis Rheum; 2017 Apr; 46(5):657-664. PubMed ID: 27998620
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histological parameters helpful in recognising steroid-treated temporal arteritis: an analysis of 35 cases.
    Font RL; Prabhakaran VC
    Br J Ophthalmol; 2007 Feb; 91(2):204-9. PubMed ID: 16987903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is statin exposure associated with occurrence or better outcome in giant cell arteritis? Results from a French population-based study.
    Pugnet G; Sailler L; Bourrel R; Montastruc JL; Lapeyre-Mestre M
    J Rheumatol; 2015 Feb; 42(2):316-22. PubMed ID: 25512477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Cost-Effectiveness of Tocilizumab (Actemra) Therapy in Giant Cell Arteritis.
    Jogimahanti AV; Kini AT; Irwin LE; Lee AG
    J Neuroophthalmol; 2021 Sep; 41(3):342-350. PubMed ID: 34415267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic factors and long-term evolution in a cohort of 133 patients with giant cell arteritis.
    Hachulla E; Boivin V; Pasturel-Michon U; Fauchais AL; Bouroz-Joly J; Perez-Cousin M; Hatron PY; Devulder B
    Clin Exp Rheumatol; 2001; 19(2):171-6. PubMed ID: 11326479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment failure in giant cell arteritis.
    Unizony SH; Bao M; Han J; Luder Y; Pavlov A; Stone JH
    Ann Rheum Dis; 2021 Nov; 80(11):1467-1474. PubMed ID: 34049857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of recurrent ischemic optic neuropathy in giant cell arteritis.
    Chan CC; Paine M; O'day J
    J Neuroophthalmol; 2005 Mar; 25(1):14-7. PubMed ID: 15756126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes.
    Proven A; Gabriel SE; Orces C; O'Fallon WM; Hunder GG
    Arthritis Rheum; 2003 Oct; 49(5):703-8. PubMed ID: 14558057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and safety of medium-dose prednisone in giant cell arteritis: a retrospective cohort study of 103 patients.
    Les I; Pijoán JI; Rodríguez-Álvarez R; Ruiz-Irastorza G; Martínez-Berriotxoa A
    Clin Exp Rheumatol; 2015; 33(2 Suppl 89):S-90-7. PubMed ID: 26016756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Giant cell arteritis and polymyalgia rheumatica: pathophysiology and management.
    Gonzalez-Gay MA; Garcia-Porrua C; Miranda-Filloy JA; Martin J
    Drugs Aging; 2006; 23(8):627-49. PubMed ID: 16964987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis.
    Nesher G; Berkun Y; Mates M; Baras M; Rubinow A; Sonnenblick M
    Arthritis Rheum; 2004 Apr; 50(4):1332-7. PubMed ID: 15077317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ustekinumab for the Treatment of Giant Cell Arteritis.
    Matza MA; Fernandes AD; Stone JH; Unizony SH
    Arthritis Care Res (Hoboken); 2021 Jun; 73(6):893-897. PubMed ID: 32248659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term remission in biopsy proven giant cell arteritis: A retrospective cohort study.
    Restuccia G; Boiardi L; Cavazza A; Catanoso M; Macchioni P; Muratore F; Soriano A; Cimino L; Aldigeri R; Crescentini F; Pipitone N; Salvarani C
    J Autoimmun; 2017 Feb; 77():39-44. PubMed ID: 27742223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients.
    Alba MA; García-Martínez A; Prieto-González S; Tavera-Bahillo I; Corbera-Bellalta M; Planas-Rigol E; Espígol-Frigolé G; Butjosa M; Hernández-Rodríguez J; Cid MC
    Medicine (Baltimore); 2014 Jul; 93(5):194-201. PubMed ID: 25181312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Horton's disease in elderly patients aged over 75: clinical course, complications of corticotherapy. Comparative study of 164 patients. Towards a reduced initial dose].
    Chevalet P; Barrier JH; Glémarec J; el Kouri D; Hamidou M; de Wazières B; Duhamel E; Jégo P; Maugars Y; Planchon B; Rodat O
    Rev Med Interne; 2001 Jul; 22(7):624-30. PubMed ID: 11508155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurence in a population-based study.
    Salvarani C; Hunder GG
    Arthritis Rheum; 2001 Apr; 45(2):140-5. PubMed ID: 11324777
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis.
    Cid MC; Font C; Oristrell J; de la Sierra A; Coll-Vinent B; López-Soto A; Vilaseca J; Urbano-Márquez A; Grau JM
    Arthritis Rheum; 1998 Jan; 41(1):26-32. PubMed ID: 9433866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.